Packaging and Distribution

The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.

From disagreement to denial, being cordial about quality control can be challenging.

Novartis Sells US Enablex Rights; Ricerca Names Chemistry Director; And More.

DSM and PolyTherics in Development Deal; Kite Pharma Appoints President and CEO, And More.

Genzyme Sells Genetics Business; Bausch and Lomb Names Vice-President; and More.

Pfizer to Acquire FoldRx; Protalix Appoints COO; And More.

Company and People Notes: Lonza Acquired Vivante; PPD Appoints VP of Quality Management; And More.

New data provide insight into pharma-industry professionals' daily lives.

Week of Aug. 23, 2010: Company and People Notes: Quark and Novartis Form Agreement; Hospira CEO Retires; And More.

Eli Lilly Ends Semagacestat Program; Selecta Appoints CEO; And More.

This week, the US Food and Drug Administration published on its website a summary of good manufacturing practices for the holding and distribution of drug products.

Penwest and Endo to Merge; Watson Makes Senior Appointments; And More.

FDA Approves Flu Vaccines; Caraco Names COO; And More.

Serialized product codes serve as the foundation of ePedigree records and product traceability.

Industry's focus on cost cutting has led to a dangerous gap in training and knowledge.

Overall Equipment Effectiveness has been shown to identify the root cause of inefficiencies.

Merck and Sinopharm Sign Agreement; Agilent Appoints CFO; And More.

Pfizer Ends Second Tanezumab Clinical Program; Catalent VP Joins USP Panel; And More.

Xcelience and Penn Form Joint Venture; Almac Appoints QA Director; And More.

Eli Lilly to Acquire Alnara Pharmaceuticals; Exelixis CEO Leaves for Biogen Idec; And More.

After a spate of industrial disasters, the public seeks greater oversight of corporations-so does FDA.

Pfizer Suspends Tanezumab Program; Actavis Appoints CEO; And More.

The effects of counterfeiting are hard to measure, both in human impact and financial loss.

With the increasing financial and technical means of counterfeiters, the number of counterfeit pharmaceuticals in the supply chain is growing at an alarming rate.

Despite the development of covert security technologies, overt solutions are still very important when it comes to product security strategies.